SCHEMBL11065

SCHEMBL11065

ClCCCN1CCOCC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
HPGD P15428 1/20 0.48
DUSP3 P51452 1/20 0.48
KDM4E B2RXH2 3/20 0.48
ALDH1A1 P00352 2/20 0.48
HRH3 Q9Y5N1 3/20 0.47
SIGMAR1 Q99720 2/20 0.47
MAPK1 P28482 2/20 0.47
CYP1A2 P05177 1/20 0.47
CHRM2 P08172 1/20 0.47
CHRM1 P11229 1/20 0.47
HTR2A P28223 1/20 0.47
SCN1A P35498 1/20 0.47
HTR2B P41595 1/20 0.47
KCNH2 Q12809 1/20 0.47
SCN2A Q99250 1/20 0.47
SCN3A Q9NY46 1/20 0.47
POLB P06746 1/20 0.47
LMNA P02545 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26621753 1.00 KEAP1 (0.60) KEAP1SMN1; SMN2HPGDDUSP3KDM4E
Hydrochloric Acid SCHEMBL10978 0.98 KEAP1 (0.58) KEAP1SMN1; SMN2HPGDDUSP3KDM4E
Hydrochloric Acid SCHEMBL23116183 0.95 KEAP1 (0.56) KEAP1SMN1; SMN2HPGDDUSP3KDM4E
SCHEMBL2746864 0.93 KEAP1 (0.58) KEAP1SMN1; SMN2HPGDDUSP3KDM4E
SCHEMBL11536090 0.91 SMN1; SMN2 (0.56) KEAP1SMN1; SMN2HPGDDUSP3KDM4E
Bicarbonate SCHEMBL28180070 0.86 LMNA (0.49) KEAP1SMN1; SMN2HPGDDUSP3KDM4E
SCHEMBL8997786 0.84 KEAP1 (0.46) KEAP1SMN1; SMN2HPGDDUSP3KDM4E
SCHEMBL40041 0.84
SCHEMBL1998867 0.84 KEAP1 (0.71) KEAP1SMN1; SMN2HPGDDUSP3KDM4E
SCHEMBL7239607 0.84 KEAP1 (0.71) KEAP1SMN1; SMN2HPGDDUSP3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1769 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4452952-A1 A PREPARATION OF QUINAZOLINEDIONES AND USE THEREOF Council of Scientific and Industrial Research, an Indian Registered Body Incorporated under Regn. of Soc. Act (Act XXI of 1860) (IN) 2024-10-30 EP claimed
CN-118812567-A Nasopharyngeal carcinoma resisting photosensitizer with photothermal and photodynamic effects and preparation method and application thereof 湘南学院 2024-10-22 CN claimed
CN-118717774-A Preparation method of small molecular compound GI-Y3 and application of small molecular compound GI-Y3 in preparation of anti-cell apoptosis drugs and inhibitors 温州医科大学附属第一医院 2024-10-01 CN claimed
CN-118420595-A STING agonist ST-76 and synthetic method and application thereof 河南牧业经济学院 2024-08-02 CN claimed
CN-117777098-A 4-aminoindazole double-target inhibitor and preparation method and application thereof 成都市第三人民医院 2024-03-29 CN claimed
CN-114920704-B Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application 暨南大学 2023-11-03 CN claimed
WO-2023119320-A1 A PREPARATION OF QUINAZOLINEDIONES AND USE THEREOF COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) 2023-06-29 WO claimed
CN-114920704-A Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application 暨南大学 2022-08-19 CN claimed
EP-3609875-B1 AN IMPROVED PROCESS FOR THE PREPARATION OF N-(3-ETHYNYLPHENYL)-7-METHOXY-6-(3-MORPHOLINOPROPOXY) QUINAZOLIN -4-AMINE DIHYDROCHLORIDE NATCO PHARMA LTD (IN) 2021-10-20 EP claimed
US-11091470-B2 Process for the preparation of N-(3-ethynylphenyl)-7-methoxy-6-(3-morpholinopropoxy) quinazolin-4-amine dihydrochloride NATCO PHARMA LIMITED (IN) 2021-08-17 US claimed
CN-102675246-B Preparation method of pramoxine hydrochloride JINAN CHENGHUI SHUANGDA CHEMICAL CO LTD 2014-04-23 CN claimed
CN-103524433-A Method for synthesizing gefitinib and intermediate thereof TIANJIN PHARMACN MEDICAL TECHNOLOGY CO LTD 2014-01-22 CN claimed
CN-103304491-A Preparation method of gefitinib LIANYUNGANG SHENGHE BIOTECHNOLOGY CO LTD 2013-09-18 CN claimed
CN-103012290-A Preparation method of high-purity gefitinib QILU PHARMACEUTICAL CO LTD 2013-04-03 CN claimed
CN-101148439-B Preparing method for gefitinib UNIV SOUTHEAST 2011-06-22 CN claimed
CN-102030716-A Method for preparing gefitinib UNIV SUN YAT SEN 2011-04-27 CN claimed
CN-101205214-B Benzimidazole compound for anti-inflammatory and analgesic UNIV SHENYANG 2011-02-16 CN claimed
CN-101570516-B Method for preparing 4-(3-chlorine-4-fluorophenylalanine)-7-methoxy-6-[3-(4-morpholinyl) propoxy] quinazoline CHONGQING WORLD HAORUI PHARM CHEM CO LTD 2011-01-05 CN claimed
CN-101570516-A Method for preparing 4-(3-chlorine-4-fluorophenylalanine)-7-methoxy-6-[3-(4-morpholinyl) propoxy] quinazoline CHONGQING WORLD HAORUI PHARM C (CN) 2009-11-04 CN claimed
CN-101148439-A Preparing method for gefitinib UNIV SOUTHEAST (CN) 2008-03-26 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11091470-B2 Process for the preparation of N-(3-ethynylphenyl)-7-methoxy-6-(3-morpholinopropoxy) quinazolin-4-amine dihydrochloride MAP7, NQO2, ABL1 KEAP1 119/4885SMN1; SMN2 915/4885HPGD 1016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.